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Background: Colorectal cancer survival is better in hereditary nonpolyposis colorectal cancer
patients than in sporadic colorectal cancer patients and even for hereditary nonpolyposis
colorectal cancer with colorectal cancer is not consensual that extensive colectomy is prefer-
able  to partial colectomy. This study analyzes and compares the long-term results of these
two  groups of patients submitted to curative subtotal colectomy or total colectomy.
Methods: Between 2002 and 2018, 68 patients with colorectal cancer without familial ade-
nomatous polyposis were submitted to a total or subtotal colectomy in a single tertiary
center. The patients were divided in two groups: hereditary nonpolyposis colorectal cancer
patients (with Amsterdam criteria) and sporadic colorectal cancer patients (the others). The
presence of Amsterdam criteria for hereditary nonpolyposis colorectal cancer and germline
mutation  for mismatch repair genes was confirmed by clinical records. Results and survival
were analyzed following surgery.
Results: We  obtained a sporadic colorectal cancer group with 31 patients and a hereditary
nonpolyposis colorectal cancer group with 37 patients. The two  groups differ in age but not
in  gender, tumor stage or surgical morbidity. The overall survival and disease-free survivalups but even better for hereditary nonpolyposis colorectal cancer groupwere  good in both growith  statistical significance when comparing the two groups.
Conclusion: Total or subtotal colectomy for colorectal cancer provides a good survival. These
surgical procedures should be considered the first option for colorectal cancer in young
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hereditary non polyposis colorectal cancer patients. In those cases, they provide good long-
term  results, avoiding the risk of metachronous colorectal cancer and the surveillance is
restricted only to the remaining need for rectum.
© 2019 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. This is
an  open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Colectomia  extensa  em  cancro  colorretal  e  cancro  colorretal  hereditário
sem  polipose  –  resultados  a  longo  prazo
Palavras-chave:
Cancro colorretal
HNPCC
Síndrome de Lynch
Instabilidade
Genes de reparac¸ão do ADN
Colectomia total
r  e  s  u  m  o
Introduc¸ão: A sobreviveˆncia do cancro colorretal é melhor em pacientes com cancro col-
orretal hereditário não associado a polipose do que em pacientes com cancro colorretal
esporádico. Mesmo em casos de cancro colorretal hereditário sem polipose, a preferência
pela  colectomia total em relac¸ão à parcial não é consensual na literatura. Este estudo anal-
isa  e compara os resultados a longo prazo destes dois grupos de pacientes submetidos à
colectomia curativa subtotal ou total.
Métodos: Entre 2002 e 2018, 68 pacientes com cancro colorretal sem polipose adenomatosa
familiar foram submetidos a colectomia total ou subtotal em um único centro terciário. Os
pacientes foram divididos em dois grupos: aqueles com cancro colorretal hereditário sem
polipose (de acordo com os critérios de Amsterdão) e os com cancro colorretal esporádico
(os  demais). Os critérios de Amsterdão para cancro colorretal hereditário sem polipose e a
presenc¸a  de mutac¸ão germinativa para os genes de reparac¸ão de ADN foram confirmados
por consulta dos registros clínicos. Os resultados e a sobrevivência foram analisados após
a  cirurgia.
Resultados: No presente estudo, 31 pacientes foram incluídos no grupo de cancro colorretal
esporádico e 37 no grupo de cancro colorretal hereditário sem polipose. Diferenc¸as signi-
ficativas foram observadas em relac¸ão à idade, mas não ao ge´nero, estadio do tumor ou
morbilidade cirúrgica. A sobreviveˆncia global e a sobreviveˆncia livre de doenc¸a foram boas
em  ambos os grupos, mas os resultados foram ainda melhores no grupo de cancro colorretal
hereditário sem polipose, com significado estati´stico.
Conclusão: A colectomia total ou a colectomia subtotal para o cancro colorretal propor-
cionam uma boa sobreviveˆncia e devem ser consideradas a primeira opc¸ão de tratamento
em  pacientes jovens com cancro colorretal hereditário sem polipose. Nestes pacientes,
uma  cirurgia co´lica mais extensa permite a obtenc¸ão de bons resultados a longo prazo;
reduz o risco de cancro colorretal meta´crono e restringe a vigilância endosco´pica ao reto
remanescente.
©  2019 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda. Este
e´  um artigo Open Access sob uma licenc¸a CC BY-NC-ND (http://creativecommons.org/Introduction
Hereditary nonpolyposis colorectal cancer (HNPCC, Lynch
syndrome) is a genetic disease of autosomal dominant inheri-
tance due to germline mutations in mismatch repair (MMR)
genes MLH1, MSH2, MSH6, PMS2 or epigenetic silencing of
MSH2 via inherited EPCAM mutations,1,2 which carries a
cumulative risk by age 70 years of 26%–80% for colorec-
tal cancer (CRC).3 Mutation carriers also are at risk for
several extra-colonic cancers, particularly cancers of the
endometrium, ovary, urothelium, small bowel, stomach and
4brain.
Its prevalence in the general population is about 1 in 500,
and it causes about 2%–3% of all colorectal cancers. The muta-
tion in one of four genes of the DNA mismatch repair systemlicenses/by-nc-nd/4.0/).
also confers a markedly increased risk for other types of can-
cer, namely of endometrium.5,6
The presence of HNPCC is suspected when a patient devel-
ops cancer at an unusually young age or because of familial
clustering. Usually patients with CCR who meet the Amster-
dam criteria (Table 1) are HNPCC patients by definition.7 In
families that meet the Amsterdam criteria, the probability of
having a mutation in MLH1, MSH2 genes is high (50%–92%).8,9
Currently the Amsterdam criteria also still covers families
with no evidence of a DNA repair defect in a tumor, in which
the increased tumor risk is probably due to genetic causes
that have not yet been identified.10 The familial nature of
colon cancer is also caused, to an unknown extent, by sim-
ple coincidence. HNPCC patients also include those who  meet
the weaker criteria of the Bethesda Guidelines11 (Table 1) and
have a tumor with an MMR defect. The Bethesda Guidelines
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Table 1 – Amsterdam II Criteria and Revised Bethesda Guidelines.
Amsterdam II Criteria (Vasen et al.7)
All criteria must be met:
Three or more relatives with histologically confirmed colorectal cancer or cancer of the endometrium, small bowel, ureter, or renal pelvis,
one affected relative being a first-degree relative of the other two; FAP should be excluded;
Two or more successive generations are affected;
At least one relative was diagnosed before the age of 50 years
Revised Bethesda Guidelines (Rodriguez-Bigas et al.11)
One or more of the following criteria must be met:
Colorectal cancer before the age of 50 years;
Synchronous or metachronous colorectal cancer or other HNPCC-related tumorsa, regardless of age;
Colorectal cancer with MSI-high morphologyb before the age of 60 years;
Colorectal cancer (regardless of age) and a first-degree relative with colorectal cancer or an HNPCC-related tumor before the age of 50 years;
Colorectal cancer (regardless of age) and two or more first- or second-degree relatives diagnosed with colorectal cancer or an HNPCC-related
tumor (regardless of age)
FAP, familial adenomatous polyposis; HNPCC, hereditary nonpolyposis colorectal cancer; MSI, microsatellite instability.
a HNPCC-related tumors include colorectal, endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract, and brain (usually
glioblastoma as seen in Turcot syndrome) tumors, sebaceous gland adenomas and keratoacanthomas in Muir–Torre syndrome, and carcinoma
of the small bowel.
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between surgery and last observation or dead. When calculat-b Presence of tumor-infiltrating lymphocytes, Crohn’s-like lymphocyt
pattern.
ave a higher sensitivity but lower specificity than the Amster-
am criteria regarding evidence of a mutation in an MMR gene.
ll patients carrying a cancer-causing germline mutation in
n MMR  gene (almost half of HNPCC patients) can also be
aid to have Lynch syndrome. However, in clinical practice
he terms “HNPCC” and “Lynch syndrome” are usually used
ynonymously.12
Usually for Lynch syndrome confirmation, the tumor tissue
s analyzed for evidence of deficient mismatch repair. If such
vidence is found, a genetic mutation is sought. The identifi-
ation of a pathogenic mutation by genetic test confirms the
iagnosis in the patient and enables predictive testing of other
amily members.13
Yet, the identification of MMR  gene mutation is not always
chieved and the diagnosis, the therapeutic plan and surveil-
ance are made taking into account the other cardinal features
esides the earlier average age of cancer onset, including
RC mainly in right colon, accelerated carcinogenesis, high
isk for metachronous colorectal cancers, specific pathology
eatures for HNPCC colorectal cancers (they are more  often
oorly differentiated and have an excess of mucoid and signet
ell features, a Crohn-like reaction and an excess of infil-
rating lymphocytes within the tumor)14 and importantly, an
ncreased survival when compare with sporadic colorectal
ancer patients.
These aspects have clinical implications for HNPCC
atients with CRC management namely, extension of surgi-
al resection, the need of chemotherapy in CRC Stage III and
requency of screening colonoscopies when partial colectomy
s done to detriment of a total or subtotal colectomy.15 In fact,
he concept that more  extensive colonic resection in the CRC
nd in particular in the HNPCC does provide survival advan-
age is not proven and the surgical policy varies in different
enters. For this specific reason we  carry out the present study
hich aims to analyze long-term results after total or subtotal
olectomy in colorectal cancer, especially concerning patients
ith Amsterdam criteria and based on results achieved toction, mucinous/signet-ring cell differentiation, or medullary growth
determinate the most appropriate extension of surgical
resection in this group of patients.
Methods
Database  design,  patient  population  and  inclusion  criteria
The study was an open observational study without a con-
trol group. All patients were 20 years of age or older at
inclusion. Age at inclusion was the patient age when they
were submitted to elective total/subtotal colectomy or colec-
tomy totalization. We included all patients with colon cancer
without familial adenomatous polyposis (FAP) submitted to
a curative total, subtotal colectomy or colectomy totaliza-
tion between December 2002 and April 2018 in a single
tertiary referral center. Other diagnosed neoplasia, presence
of rectal cancer, clinical Stage IV and R1/R2 surgery were
exclusion criteria but not the clinical patient history of pre-
vious colonoscopy with polypectomy or a previous surgery for
CRC.
The patients were divided in two groups: HNPCC patients
(patients with Amsterdam criteria) and SCRC patients (the
others). All the patients have a colon cancer diagnosis with-
out other neoplasm. All patients were subjected to follow-up
according to international guidelines. The patients were fol-
lowed until the last update of information, and scored as alive
without disease, alive with disease and dead.
The following information was used for this report: gen-
der, presence of Amsterdam criteria, genetic variant when
identified, age at surgery, age and stage of previous CRC and
surgery type and date if any, surgery extension and date,
surgery morbimortality cancer stage, numbers of monthsing survival, each patient was scored once only, irrespective
of how many  surgeries for cancer the patient might have
had.
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Diagnosis
Total colonoscopy with a biopsy-proven adenocarcinoma,
chest, abdominal and pelvic computed tomographic scan, and
serum carcinoembryonic antigen (CEA) level.
Surgical  procedures
Surgery consisted mainly of total or subtotal colectomy. For
patients with previous partial colectomy the surgery realized
was totalization of colectomy.
The term of “subtotal colectomy” is used for the authors
only for the extensive colectomy in which part of the sigmoid
and sigmoid arteries were spared in a near total colectomy.
For authors the synonymous of “partial colectomy” are
“segmental colectomy”. This term includes “right colectomy”,
“left colectomy”, “sigmoidectomy” or “transverse colectomy”.
Regarding the selection of the operative procedure, we
considered the presence of CRC with Amsterdam criteria, syn-
chronous CRC, metachronous CRC or CRC with polyps not
removable by colonoscopy.
Resected  specimen  samples  –  H&E  staining;  analysis  for
deficient  of  MMR
Standard pathological tumor staging of the resected spec-
imen was performed in accordance with the guidelines
of the American Joint Committee on Cancer (http://www.
cancerstaging.net).
Tumor tissue was analyzed for evidence of loss of mis-
match repair protein expression by immunohistochemistry or
by microsatellite instability test. When positive the pathogenic
mutation by genetic test (denaturing high performance liquid
chromatography analysis and DNA sequencing) was realized.
Adjuvant  chemotherapy  protocol
Post-surgery patients with pathological Stage III were admin-
istered adjuvant chemotherapy protocol for 6 months
performed preferably with 5-FU or a combination of 5-FU
and oxaliplatin (one of the followed regimens: mFolFOX6 –
200 mg/m2 folinic acid (FA) day 1, 400 mg/m2 5-FU bolus day 1,
continued infusion for 46 h of 2400 mg/m2 5-FU and 85 mg/m2
oxaliplatin, 14/14 day cycle; CapeOx: 1000 mg/m2 capecitabine
twice a day, days 1–14, 130 mg/m2 oxaliplatin day 1, 21/21 day
cycle; 5-FU/FA: 200 mg/m2 FA day 1, 400 mg/m2 5-FU bolus
day 1, continued infusion for 46 h of 2400 mg/m2 5-FU, 14/14
day mFolFOX6 or CapeOX were the preferred regimens. When
the administration of oxaliplatin is not possible due to side
effects of the drug or the comorbidities of the patient, one
of followed regimens was used: 5-fluorouracil/folinic acid (5-
FU/FA) 200 mg/m2 folinic acid (1 h infusion prior to 5-FU) and
400 mg/m2 5-FU per day intravenously once daily × 5 every
5 weeks or 1000 mg/m2 capecitabine twice a day × 5 every 5
weeks.Survival  and  disease  recurrence  definitions
Disease recurrence was evaluated according to location:
locoregional (LR), systemic (DR) or mixed. All surviving 1 9;3  9(3):223–230
patients were followed-up and their current status was
confirmed. None of the patients were lost from follow-up.
Disease-free survival (DFS) was calculated from the date
of surgery to the date of progression (local or distant), and
overall survival (OS) was calculated from the date of surgery
to the date of death or last follow-up.
Statistical  analysis
The HNPCC group and the SCRC group were compared in rela-
tion to age (Student’s t-test) and in relation to sex, stage and
morbidity (Chi-square test).
Overall survival and disease-free survival were estimated
in the 68 patients studied and also in the two groups using the
Kaplan–Meier method.
The difference in survival rates between the two  groups
was tested for significance using the log-rank test. Survival
was compared with the log rank test.
The statistical analysis was made with SPSS statistical soft-
ware  (version 21.0 for Windows; SPSS Inc., Chicago, IL). All
statistical tests were conducted at a two-sided level of signif-
icance of 0.05.
Ethics  approval
This project was approved by the Research Ethics Health Com-
mittee. Patient informed consent for the use of clinical and
genetic information was obtained.
Results
Description  of  study  population  and  clinical  parameters
This cohort study gathered 72 consecutive patients with CRC
treated with total, subtotal colectomy or totalization of colec-
tomy at one single University Hospital. After the exclusion
of 4 patients with p Stage IV, 68 patients were included in
the present analysis, with a median age of years 58.7 (range
30–86 years). The male to female ratio was 1.72:1. Patients were
divided in two groups – HNPCC group (patients with Amster-
dam criteria): 37 and SCRC group (the others): 31. The clinical
parameters are summarized in Table 2.
Surgery
Total colectomy was performed in 42 (61.7%) patients;
subtotal colectomy in 17 (25%) patients and totalization
of colectomy in 9 (13.2) patients. In 26 (38.2%) patients
the surgical approach was laparoscopic. The perioperative
morbidity of the series was 23.5%, with 5 (7.3%) abdom-included 8 (11.7) reoperations (due to five leakages and three
abdominal abscesses), without re-admissions or mortality
(Table 3).
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Table 2 – Clinical parameters.
Entire sample(n  = 68) HNPCC group(n = 37) SCRC group(n = 31) p
Age 58.7 52.3 66.5 <0.001
Male 43 25 18 0.59
Previous CRC 9 7 2
Synchronous CRC 20 12 6
CRC + polyps 43 21 22
CRC location
Right colon 31 18 13
Transverse colon 13 5 8
Left colon 19  11 8
Sigmoid colon 14  6 8
Time between diagnosis and surgery (days) 42 41 43
Table 3 – Surgical parameters.
Entire samplen = 68 (%) HNPCC groupn = 37 (%) SCRC groupn = 31 (%) p
Surgery
Total/colectomy 42 23 19
Subtotal/colectomy 17 7 10
Totalization/of/colectomy 9 7 2
Morbidity
Postoperative ileus 16 (23.5%) 9 (24.3%) 7 (22.5%)
Abdominal/infection 6 4 2
Abscess 3 1 2
Anastomotic leak 2 1 1
Reintervention 0.87
With temporary stoma 5 3 2
With abdominal/washout 3 1 2
Readmission 0 0 0
Posterior surgery for stoma closure 5 3 2
Mortality 0 0 0
p=0.87 (includes morbidity, reintervention, readmission and posterior surgery for stoma closure), not only reintervention.
Table 4 – Pathologic and genetic parameters.
Entire sample(n  = 68) HNPCC group(n = 37) SCRC group(n = 31) p
Tumor grade
G1 3 0 3
G2 60 33 27
G3 5 4 1
Crohn-like reaction 10 8 2
Mucinous tumor 15 9 6
“Ring signet cells” presence 3 3 0
Tumor stage 0.70
Stage I 24 12 12
Stage II 23  12 11
Stage III 22 13 8
MMR gene mutation
MLH1 1 1 0
MSH2 8 8 0
MSH6 3 3 0
0 
2 
P
S
o
(
APMS2 0 
EPCAM mutation 2 
athology  of  resected  specimens  and  genetic  test
tage distribution is shown in Table 4. The average number
f dissected lymph nodes in the surgical specimens was 23
range 18–55). All resected specimens were R0.Genetic mutation was identified in 14 patients of 37 with
msterdam criteria.0
0
Clinical  outcome
Table 5 shows long-term clinical outcome, relapse of disease
and survival.The mean of patients follow-up was 79.5 months (range
6–190).
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Table 5 – Long-term results after extensive colectomy in CRC. Mean of follow-up: months 79.5 (range 6–190).
Entire sample (n = 68) HNPCC group (n = 37) SCRC group (n = 31) p
Bowell movements per day 1.7 1.7 1.8
Surgery related with total/subtotal colectomy or totalization of colectomy 5 3 2
OS 0.001
1 year 100% 100% 100%
2 year 100% 100% 100%
3 year 96.3% 100% 92.6%
5 year 89.9% 100% 79.5%
DFS 0.013
1 year 97.0% 100% 93.4%
2 year 97.0% 100% 93.4%
91.4%
87.2%3 year
5 year 
Concerning functional results: these patients have not
dietary restriction, regular medication for stool regulation,
night time defecation, use of pad daytime or at night, soiling
or seepage during day time or night or urgency of defecation.
Also, they have not any social handicap.
The 24 h stool frequency was 1.7.
Five of the 68 patients had other surgical procedures related
with the total/subtotal colectomy or totalization of colectomy.
For example, intestinal reconstruction (HNPCC-3 and SCRC-2).
For global sample 5 year OS was 89.9% and 5 year DFS was
87.2%.
When compared OS and DFS for HNPCC and SCRC groups,
survival was significantly higher in HNPCC group (p = 0.001 and
p = 0.013).
From total sample (68 patients) only nine patients (13.2%)
developed distant metastases (3 hepatic metastases, 3 pul-
monary metastases; 1 hepatic and pulmonary metastases and
1 hepatic and retroperitoneal lymph node metastases): 7 died
and 2 were alive with pulmonary metastases.
Discussion
CCR is one of the most frequent worldwide cancers. In the case
of non-metastatic colon cancer, segmental colectomy contin-
ues to be the treatment plan corner stone followed by adjuvant
chemotherapy for tumor Stages III.16 Most of CRC are sporadic
cancers but circa 3% are HNPCC with a more  favorable survival.
So, in those cases therapy, surveillance and genetic counseling
are necessarily different.
The first problem that arises is the HNPCC identification
in population with CRC. We know that a large number of
clinicians are still not sensitized for screening and in most
centers the systematic detection of microsatellite instability
in patients with colon cancer and age under 70 years is not
yet implemented. In the other hand, about 15% of sporadic
cancer shows microsatellite instability and there are patients
with Amsterdam criteria in which microsatellite instability is
negative. For that reason, in our center the policy adopted for
patients with Amsterdam criteria regardless the identification
or not of the genetic mutation that have the first CRC was
a more  extensive colectomy instead a segmental colectomy.
This explains why a considerable number of patients with
Amsterdam criteria and microsatellite instability negative test
were submitted to a more  extensive colectomy in our sample. 96.2% 86.0%
 96.2% 77.2%
The second issue is related with the concept that more
extensive colonic resection in the CRC and in particular in
the HNPCC does provide survival advantage. Surgical man-
agement of colon cancer for patients with Lynch Syndrome
who carry a mismatch repair gene mutation is controversial.
Actually, current recommendations in the USA, suggest that
persons with Lynch syndrome undergoing surgical resection
of a colon cancer should be offered to extensive resection
rather than a segmental resection, even though this policy
has not previously been proven to be superior to a policy of 1–2
yearly colonoscopic surveillance.17 Despite this recommenda-
tion, the extent of resection performed varies between centers
in the USA. For example, the Cleveland Clinic performed
total colectomy for 16 of 33 CRC patients from Amsterdam
criteria-positive families compared with seven of 60 from
clinics elsewhere in the USA.18 In Europe, on the basis of
a decision analysis study9 and the documented high risk of
a metachronous cancer, current guidelines recommend the
option of extensive resection be discussed with patients, par-
ticularly those under the age of 50 years.19 In fact, there are
no controlled studies available that address the question of
whether radical surgery is appropriate. Any decision on radi-
cal surgery, up to and including colectomy, would need to take
into account the risk of surgery, the patient’s age and sex,
long-term medical prognosis, and the quality and capacity
to do annual colonoscopy surveillance with preventive ade-
noma removal. In fact, the decision to remove more  or less of
the colon involves the consideration of a relatively high risk
of metachronous Colorectal Cancer (CRC) with the impact of
more extensive surgery quality of life.20 The relatively high
risk of metachronous CRC, i.e. primary CRC diagnosed more
than 12 months after the first diagnosis of primary colon can-
cer, (16% after 10 years)21 supports a more  aggressive primary
surgical approach involving the removal of all, or at least most,
of the colon after diagnosis.22 The functional consequence of
an increase in bowel frequency and possible negative impact
on quality of life might be balanced against the reduction in
risk of metachronous CRC afforded by more  extensive surgery,
particularly if the person is aged less than 60 years at the time
of surgery.23 On the other hand, surveillance of the remaining
colon and rectum will be required after most surgery and the
inconvenience of yearly colonoscopy (with the requirement
for standard bowel preparation rather than enema prepara-
tion) may be offset by the better functional outcome after
segmental surgery. This clinical equipoise is reflected in world
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urgical opinion4,24 and our opinion is in favor of a more  exten-
ive surgery.
Based on these assumptions we analyzed first the long-
erm overall results of our sample and then the same sample
ivided into two groups: patients in two groups with Amster-
am criteria that we named HNPCC group and the other
atients with CRC but without criteria of Amsterdam where
he surgery was more  extensive due to the presence of
etachronous neoplasms or the presence of polyps that could
ot be endoscopically easily removed.
As the first analysis of the overall sample we  can consider
s good the results of patients treated with a more  exten-
ive surgery. The morbidity of the surgery was the expected,
ithout definitive stomas and without mortality. The mean of
ovements bowel number per day were 1.7, without dietary
estriction, need of medication for stool regulation or social
andicap; there were few subsequent abdominal surgeries
elated to the total/subtotal colectomy; the overall survival
nd disease-free survival were good (5 year, OS: 89.9%; 5 year,
FS: 87.2%). So, in our series morbidity and functional quality
f a more  extensive surgery were acceptable without a nega-
ive burden.
In the other hand, the division of the sample into two
roups allowed us to obtain two groups with differences in age
s expected but without significant differences in sex, surgery,
urgical complications and stage, which allows us to state that
he survival and survival of the first group is significantly bet-
er than that of the second group. This is in accordance with
he statement that CRC in HNPCC patients have better progno-
is and probably is not fundamental to characterized patient
ene mutation to adopt a more  extensive surgery since patient
hows Amsterdam criteria.
Finally, the third aspect the CRC treatment of HNPCC
atient: patients with microsatellite-unstable tumors have
 better prognosis than those with stable tumors (probably
ue to an immune response to tumor cells). This means
hat there may be less benefit from adjuvant therapy. Sev-
ral retrospective studies have shown that patients with
icrosatellite-unstable Stage II and III colon cancer do not
enefit from adjuvant 5-FU-based chemotherapy.25 Ongoing
esearch is investigating whether this is also true for colon
ancers in HNPCC patients. This aspect was not considered in
ur series. All the patients with tumor Stage III were treated
ith adjuvant chemotherapy which does not interfere with
he results presented.
The strength of our study includes long mean follow-
p, data and surgery realized in a single center. There are
ome limitations inherent to this study: the small number
f patients and a small number of patients with genetic
utation confirmation. This is a technical difficulty that we
ace in the last years in our center. We intend in the future
evised all Formalin-Fixed Paraffin-Embedded blocks of tumor
esected specimens (FFPE tissue sample) from the Pathology
epartment at our Hospital and repeated the microsatellite
nstability analysis by immunohistochemistry and by PCR. In
eantime the missing know of genetic mutation status has
ot prevented that it may be considered a good policy to adopt
 more  extensive colic surgery whenever the patient presents
msterdam criteria.;3 9(3):223–230 229
The virtue of this study is warning the need for large-scale
studies to confirm the advantage of more  extensive colon
surgery for patients with CRC, especially for the first CRC in
patients with Amsterdam criteria.
Conclusion
Total or subtotal colectomy in CRC provides a good sur-
vival. These surgical procedures should be considered the first
option for colorectal cancer in young HNPCC patients. In those
cases, they provide good long-term results, avoiding the risk
of metachronous CRC and surveillance is restricted only to the
remaining rectum.
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